摘要
目的研究注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白(etanercept)对活动性类风湿关节炎(RA)患者的疗效和安全性。方法89例患者随机分为试验组和对照组。试验组皮下注射etanercept治疗,每周2次,每次25mg;对照组每周1次口服甲氨喋呤(MTX,每周12.5mg),疗程12周。结果治疗2周后,etan-ercept组ACR20有效率为44.4%,MTX组为22.5%,组间比较差异有统计学意义(P<0.05)。治疗8周后,et-anercept组与MTX的ACR20有效率组间比较差异有统计学意义(P<0.05)。治疗12周后,etanercept组ACR20有效率为66.7%,MTX组为42.50%,组间比较差异有统计学意义(P<0.05)。两组不良反应无明显差别。结论和口服MTX相比,采用etanercept治疗活动性RA能更快的缓解症状,具有良好的安全性和显著的疗效。
Objective To evaluate the effect and safety of recomnbinant human tumor necrosis factor - α Receptor Ⅱ （etanercept） for treatment of rheumatoid arthritis （RA）. Methods 89 patients were divided into control group and trial group randomly. 25 mg etanercept was given to trial group twice a week by subcutaneous injection;While the control group accepted methotrexat （MTX） 12. 5 mg once a week orally,the course of treatment was 12 weeks. Results ACR20 effective rate of etanercept was 44. 40% after treatment for 2 weeks, while the control group was 22.50%, group com- parison has statistical significance（ P 〈 0. 05 ）. After 8 weeks, there was statistical difference between two groups（ P 〈0.05）. In the 12th weeks,the ACR20 effective rate of etanercept raised to 66.70% while the control group was 42.50%, group comparison has statistical significance （ P 〈 0.05 ）. Of safety, as well as side effect has no difference in two groups. Conclusion In comparison with MTX orally for treatment of activated rheumatoid arthritis, etanercept relieves symptoms more quickly, and it has satisfactory safety and significant effect.
出处
《医药论坛杂志》
2007年第17期44-45,48,共3页
Journal of Medical Forum
关键词
肿瘤坏死因子
重组融合蛋白
甲氨喋呤
类风湿关节炎
Tumor necrosis factor
Recombinant fusion protein
Methotrexat
Rheumatoid arthritis
